Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Entera Bio (ENTX) Gross Margin (2019 - 2024)

Entera Bio has reported Gross Margin over the past 5 years, most recently at 15.79% for Q2 2024.

  • For the quarter ending Q2 2024, Gross Margin changed N/A year-over-year to 15.79%, compared with a TTM value of 4.04% through Mar 2025, changed N/A, and an annual FY2024 reading of 4.97%, changed N/A over the prior year.
  • Gross Margin came in at 15.79% for Q2 2024, down from 42.86% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 53.57% in Q3 2021 to a low of 9.17% in Q2 2021.
  • Median Gross Margin over the past 4 years was 25.0% (2022), compared with a mean of 29.4%.
  • The largest YoY upside for Gross Margin was 2528bps in 2022 against a maximum downside of -3291bps in 2022.
  • Over 4 years, Gross Margin stood at 11.31% in 2020, then skyrocketed by 55bps to 17.58% in 2021, then surged by 144bps to 42.86% in 2022, then tumbled by -63bps to 15.79% in 2024.
  • Per Business Quant, the three most recent readings for ENTX's Gross Margin are 15.79% (Q2 2024), 42.86% (Q4 2022), and 25.0% (Q3 2022).